Form 4: ARS Pharmaceuticals' Chief Medical Officer Sarina Tanimoto Sells Shares

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock on October 8, 2024, as disclosed in a Form 4 filing with the SEC.

Summary

• Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock on October 8, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan established on March 31, 2023.
• The shares were sold in two transactions, each involving 50,000 shares, with weighted average sale prices of $13.8277 and $13.8278 respectively.
• Following the reported transactions, Tanimoto directly owns 3,407,847 shares of common stock.
• Tanimoto also has indirect ownership through various trusts, including the Richard Lowenthal Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and the Sarina Tanimoto Charitable Remainder UniTrust, as well as spousal holdings.
• The filing indicates that Tanimoto disclaims beneficial ownership of securities held by the Richard Lowenthal Charitable Remainder UniTrust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the stock sale was conducted under a pre-arranged 10b5-1 trading plan, suggesting it's not necessarily indicative of the executive's current outlook on the company.

Industry Context

Executive stock sales are a common occurrence and are often scrutinized by investors for insights into a company's prospects. Sales under a 10b5-1 plan are generally viewed as less indicative of current sentiment, as they are pre-planned.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The sale does not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates